Introduction
============

In the brain, ion channels regulate a variety of cellular processes such as neurotransmitter release, neuronal excitability, and plasticity. They are crucial in the generation and propagation of action potentials. Dysfunction of these channels causes several pathologies called channelopathies. In order to treat these channelopathies, many ion channels have been targets of small molecules and biological drugs. Overall, ion channels represent 19% of all human protein targets ([@B91]). To date, 177 ion channels-based drugs have been approved as treatments for various pathologies and disorders ([@B91]). Central nervous system (CNS) pathologies were associated with dysregulation of ion channels such as voltage gated Na^+^, K^+^, and Ca^2+^ channels. Calcium channels are the most studied among ion channels since Ca^2+^ ions in addition to controlling the cell excitability, they act as second messengers that convert electrical signals into chemical activity ([@B82]). On the other hand, to control neuronal excitability, potassium channels repolarize neurons by extruding K^+^ ions to the extracellular space. Neurological potassium channelopathies are mainly caused by dysregulation of voltage-dependent potassium channels ([@B7]) and also of the inwardly rectifying potassium channels (Kir) which provokes an hyperexcitability seen in epilepsy ([@B96]). Mutations in the KCNT1 gene encoding for sodium -activated potassium channels cause a rare infantile encephalopathy called the migrating partial seizures of infancy ([@B4]). In other cases, mutations of KCNQ2 encoding for Kv7.2 channel provoke severe epileptic encephalopathies ([@B112]). The inward-rectifier potassium channel Kir 6.2 is encoded by KCNJ11 gene forms the major subunit of the ATP-sensitive potassium channel. Mutations in this gene cause DEND syndrome, a very rare severe form of neonatal diabetes mellitus characterized by developmental delay, epilepsy and neonatal diabetes ([@B30]). Kv7.2 and Kv7.3 are the main components of the slow voltage-gated M-channel which regulates neuronal excitability ([@B11]). Loss of function mutations of the KCNQ2 and KCNQ3 genes encoding, respectively, for Kv7.2 and Kv7.3 causes benign familial neonatal convulsions ([@B96]). A dominant missense mutation in KCNMA1 gene encoding for pore-forming α-subunit of the large conductance calcium-sensitive potassium channel (BK), has been associated with a form of generalized epilepsy and paroxysmal dyskinesia ([@B24]).

Some mutations in K~2P~ channels were reported to cause several pathologies. Birk Barel mental retardation dysmorphism syndrome is caused by a missense mutation in the maternal copy of KCNK9 gene which encodes for TASK-3 (K~2P~9.1). Loss of function of the channel was observed in homodimers and also when it forms heterodimer with TASK-1 (K~2P~.3.1) ([@B5]). Recently, *de novo* a gain of function missense mutation of KCNK4 gene encoding for TRAAK channel, was reported to cause recognizable neurodevelopmental syndrome characterized by a facial dysmorphism, hypertrichosis, epilepsy, intellectual disability/developmental delay and gingival overgrowth ([@B6]). A frameshift mutation (F139Wfsx24) in KCNK18 encoding for the calcium-activated K~2P~ channel TRESK channel was associated with migraine with aura ([@B51]). Channelopathies caused by dysfunction of potassium channels are of high interest for researchers since they may present interesting targets for potential treatments.

The most recent discovered family of two-pore domain potassium channels (K~2P~) are regulated by a variety of chemical and physical stimuli ([@B55]). In this review, we will focus on describing the role of one of the most studied K~2P~ channel, TREK-1 channel in health and disease. In addition to discussing the recent pharmacological modulators of its activity.

Trek-1 Channel
==============

TREK-1, named KCNK2 or K~2P~2.1 belongs to a large family of K~2P~ channels containing 15 members grouped in six subfamilies. K~2P~ channels are the most recent class of K^+^ channels discovered. K~2P~ channels or the two-pore domain potassium channels are tandems of four transmembrane segments (M1--M4) containing two-pore domain (P1 and P2) ([Figure 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). They possess an extended M1-P1 extracellular loop and cytosolic N- and C-termini. K~2P~ channels have a unique pore signature sequence Gly-Tyr(Phe)-Gly in the 1st pore (P1) and Gly-Leu(Phe)-Gly in the 2nd pore (P2) ([@B41]; [Figure 1](#F1){ref-type="fig"}). TREK-1 was first cloned from the mouse brain ([@B28]; [Figure 3](#F3){ref-type="fig"}). TREK-1 was named after TWIK-1 channel the first cloned K~2P~ channel ([@B54]). TREK-1 shares 28% sequence homology with TWIK-1 channel. TREK-1 is highly expressed in brain and lung, but is also present in kidney, heart and skeletal muscle. When we look at the brain localization, TREK-1 is highly expressed in several regions of the brain such as the olfactory bulb, the hippocampus, the cerebellum and the cortex ([@B28]).

![Structure and classification of K~2P~ channels. The family of K~2P~ channels is composed of 15 members grouped in six subfamilies. K~2P~ channels are two-pore domain potassium channels and the most recent class of K^+^ channels discovered. They assemble as dimers of four transmembrane segments (M1--M4) and two-pore domain (P1 and P2). They have an extended M1-P1 extracellular loop and cytosolic N- and C-termini. K~2P~ channels have a unique pore signature sequence Gly-Tyr(Phe)-Gly in the 1st pore (P1) and Gly-Leu(Phe)-Gly in the 2nd pore (P2).](fphar-10-00379-g001){#F1}

![Polymodal TREK-1 regulation. TREK-1 is multiregulated by a variety of physical and chemical stimuli. TREK-1 possesses different protein partners such as AKAP150, β-COP, Mtap2, and sortilin. Sortilin interacts with TREK-1 an address it to the plasma membrane. Spadin is a synthetic peptide derived from sortilin which was shown to block TREK-1 with high affinity. Spadin antidepressant activity appears to be mediated through PI3K and Akt activation. TREK-1 is involved in numerous CNS pathologies such as depression, ischemia, epilepsy and pain.](fphar-10-00379-g002){#F2}

![Key milestones in discovery of TREK-1 channels. The scheme presents the major dates from the cloning of TREK-1 channels to the discovery of its role in physiology and pathology. AA, arachidonic acid; GPCR, G-protein Coupled Receptor; STAR^∗^D, Sequenced Treatment Alternatives to Relieve Depression. Green and Red triangles represent TREK-1 activation and inhibition processes, respectively.](fphar-10-00379-g003){#F3}

TREK-1 displays an outward rectification in symmetrical K^+^ condition due to an external Mg^2+^ block present at negative potential and to a voltage-dependence mechanism ([@B64]). Despite the absence of a voltage-sensing domain in K~2P~ channels, TREK-1 and some other K~2P~ channels show a strong voltage-dependency. The provenance of this voltage sensitivity comes from an ion-flux gating mechanism and the movement of three to four K^+^ ions into the high electric field of an inactive selectivity filter ([@B93]). However, this voltage-dependency is switched off by physiological stimuli such as arachidonic acid (AA) and Phosphatidylinositol bisphosphate (PIP~2~), which convert TREK-1 to classical leak channels ([@B93]). TREK-1 with TREK-2 and TRAAK are mechano- and thermo-sensitive K~2P~ channels ([@B41]). They are opened by stretch and cell swelling. TREK-1, TREK-2, and TRAAK knock-out mice are hypersensitive to mechanical force, they show mechanical allodynia and hyperalgesia during inflammation ([@B9]). It was reported that the mechanical force is transmitted to TREK-1 and TRAAK directly through the lipid bilayer ([@B10]). These channels open rapidly in response to tension and have a low threshold and broad range of tension activation ([@B9]).

Physiological Regulation of TREK-1 Channels
-------------------------------------------

TREK-1 channel is regulated by various physical and chemical stimuli ([Figure 2](#F2){ref-type="fig"}). TREK-1 is opened by mechanical stretch in cell-attached and inside-out configurations in both COS transfected cells and oocytes ([@B79]). TREK-1 opening occurs at all positive and negative potentials. When the cytoskeleton is disrupted with colchicine or cytochalasin D, TREK-1 activation by stretch was not altered ([@B79]). TREK-1 was shown to be sensitive to temperature variation in different type of cells expressing TREK-1. Heat gradually and reversibly activates TREK-1 reaching a maximum of activation at 37°C. However, at 12°C TREK-1 basal current is suppressed ([@B65]). TREK-1 heat activation needs cell integrity and cytosolic components since TREK-1 is insensitive to heat when patch membrane is excised ([@B65]). TREK-1 is activated by polyunsaturated fatty acids (PUFA) such as AA in different patch-clamp configurations: whole-cell, cell-attached, inside-out and outside-out configurations ([@B79]). AA activates TREK-1 with a dose-dependent manner and requires C-terminal part of the channel which is crucial for the activation and the inhibition following phosphorylation by the protein kinase A (PKA). PIP~2~ stimulates native striatal TREK-1 current in inside-out patch configuration ([@B13]). In Xenopus oocytes expressing TREK-1, PIP~2~ hydrolysis inhibits TREK-1 channel by modulating its voltage dependence ([@B62]). It is also known that internal acidosis induces an activation of TREK-1 channels with the involvement of C-terminal part ([@B66]). TREK subfamily members including TREK-1, TREK-2, and TRAAK are sensitive to phosphatidic acid (PA) which results from the hydrolysis of phosphatidylcholine by phospholipase D (PLD). It was shown that TREK-1 and TREK-2 but not TRAAK are positively regulated by PLD2 which selectively binds to their C-terminal domains ([@B16]).

TREK-1 Partner Proteins
-----------------------

Proteomic approach based on immunoprecipitation and mass spectrometry analysis of native channel complexes allowed the identification of a scaffolding protein called AKAP150 ([@B90]; [Figure 2](#F2){ref-type="fig"}). A-kinase anchoring protein (AKAP) anchors the regulatory subunit of PKA in proximity of substrates. AKAP150 forms signaling complexes within the neuron, these complexes are composed of PKA, PKC, PP2B (protein phosphatase 2B), PSD-95, SAP97 and ion channels ([@B26]). When anchored by AKAP150 within the post-M4 region, TREK-1 becomes an active leak channel insensitive to the stimuli, internal acidification AA, or mechanical stretch ([@B90]). The microtubule associated protein Mtap2 is another protein reported to associate with TREK-1 in the brain ([@B89]). Mtap2 binds to microtubules and stabilizes them. TREK-1 and Mtap2 colocalize in several brain regions such as the hippocampus, cerebellum, olfactory bulb, striatum and cortex. Similarly to AKAP150, Mtap2 binding to TREK-1 increases its activity ([@B89]). This increase in TREK-1 current amplitude is not due to a direct interaction with Mtap2 but results from an increase in the expression level of the channel at the plasma membrane. Within the neuron, TREK-1, AKAP150 and Mtap2 are simultaneously found in the post-synaptic terminals. This signaling complex regulates TREK-1 channel activity and its trafficking to the plasma membrane.

Using the yeast two-hybrid technique of the human cDNA library on the N-terminal region of TREK-1, a direct β-COP-TREK-1 interaction was reported ([@B48]). β-COP is a subunit of Coat Protein Complex I (COPI) whose role is to form coated vesicles and manage the retrograde traffic from the Golgi back to the endoplasmic reticulum (ER) or between different compartments inside the Golgi ([@B32]). β-COP depletion was found to decrease membrane expression of the cystic fibrosis transmembrane conductance regulator (CFTR) channel. Mutations in this chloride channel cause cystic fibrosis lung disease ([@B86]). β-COP increases TREK-1 surface expression and current amplitude. β-COP is involved in the forward transport of TREK-1 through a direct interaction with N-terminal part of the channel ([@B48]).

The most recently discovered protein partner of TREK-1 is sortilin ([@B81]; [Figure 2](#F2){ref-type="fig"}), also known as neurotensin receptor-3 (NTSR~3~) ([@B69]). Sortilin is synthetized as a precursor called prosortilin which is cleaved in the trans-Golgi compartment by the proprotein convertase furin to generate a mature sortilin and the release of a 44 amino-acid named the propeptide (PE) ([@B74]). NTSR~3~ is made of a large luminal domain, a single transmembrane segment and a short C-terminal moiety. The amount of NTSR~3~ expressed at the plasma membrane does not exceed 10% while the majority is expressed intracellularly and involved mainly in intracellular trafficking. Both NTSR~3~ and TREK-1 are markedly expressed in the prefrontal (PFC) and cingulate cortex, the amygdala, the hippocampus, the nucleus accumbens, the dorsal raphe nucleus (DRN) and the hypothalamus. The expression of TREK-1 was enhanced at the plasma membrane in COS-7 cells co-transfected with NTSR~3~ ([@B68]).

TREK-1 Heterodimerization
-------------------------

The first K~2P~ member cloned TWIK-1 ([@B54]), is expressed with TREK-1 in astrocytes ([@B119]). The expression of a functional TWIK-1 channel necessitates its heterodimerization with TREK-1 to mediate the passive conductance in astrocytes ([@B43]). As cited earlier in this review, TREK subfamily includes TREK-1, TREK-2 and TRAAK. Despite 78% of homology between TREK-1 and TREK-2, these two lipid- and mechano-activated K^+^ channels are differently regulated. Recent studies reported that functional TREK-1 heterodimers are formed with TREK-2 and TRAAK channels ([@B8]; [@B56]). The heterodimer TREK-1-TREK-2 had minimal activity at physiological pH. However, TREK-1-TREK-2 complex is activated in both alkaline and acidic environments. TREK-1-TRAAK heterodimer shows activation by both intracellular acidification and alkalinization ([@B56]). Functional TREK-1-TRAAK heterodimers are formed and present unique biophysical properties and different type of regulations ([@B8]). Heteromerization of TREK subfamily leads to diversification of K~2P~ channels and provides different kinds of regulations. Recently, it has been shown that a truncated form (TRESK-MT) of TRESK channel, a K~2P~ frequently associated with migraine, heteromerizes with and inhibits TREK-1 and TREK-2 ([@B88]). The heterodimer TRESK-TREK acts as a dominant negative increasing trigeminal sensory neuron excitability and migraine-like phenotype in mice ([@B88]).

Pharmacology of TREK-1 Channels
-------------------------------

### TREK-1 Blockers

Since the discovery of the involvement of TREK-1 in several CNS pathologies, very high interest has been devoted to find molecules modulators of its activity. As depicted in [Table 1](#T1){ref-type="table"}, search for blockers of TREK-1 activity started with the discovery of the role of TREK-1 in depression processes. Mice model of depression lacking *kcnk2* (the gene encoding for TREK-1) displays a phenotype resistant to the development of depression ([@B38]). Spadin was the first molecule that was developed in the aim to block TREK-1 channel and mimic the antidepressant-like phenotype of *kcnk2^-/-^* mice ([@B68]; [@B22]). Spadin is a peptide synthetized from the endogenous PE released after the cleavage of prosortilin by furin. Several analogs of spadin were developed afterward to improve spadin *in vivo* stability and antidepressant activity ([@B105]; [@B23]). From a library of 22 peptides, the shorter peptide sequence PE 22--28 exhibited higher inhibition potency for TREK-1 associated with an improved stability *in vivo* and antidepressant properties ([@B23]). Similar properties were found in its biotinylated product or analog G/A-PE 22--28 (where Gly is replaced by an Ala). These spadin analogs show an extremely high affinity for TREK-1 as inhibition occurs at nanomolar concentrations. More interesting, spadin and analogs are specific blockers for TREK-1 as no effect was observed on both TREK-2 and TRAAK, the two closest K~2P~ members to TREK-1 which belong to the same subfamily and share almost 80% of homology ([@B73]; [@B23]).

###### 

TREK-1 blockers.

                                   Molecule               IC50             Cell type               Specificity                                                                                                             References
  -------------------------------- ---------------------- ---------------- ----------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------
  Peptides                         Spadin (PE 12--28)     70 nM            COS, HEK, hTREK-1/HEK   Specific for TREK-1 channels, no effect on TREK-2, TRAAK, TASK or TRESK channels                                        [@B68]
                                   PE 22--28              0.12 nM          hTREK-1/HEK                                                                                                                                     [@B23]
                                   Biotin-PE 22--28       nd               hTREK-1/HEK                                                                                                                                     [@B23]
                                   G/A-PE 22--28          0.1 nM           hTREK-1/HEK                                                                                                                                     [@B23]
                                   Biotin-G/A-PE 22--28   1.2 nM           hTREK-1/HEK                                                                                                                                     [@B23]
  SSRIs                            Fluoxetine             19 μM            tsA 201 cells           Antagonize TREK-2 (IC50 = 28.7 ± 7.6 μM), SERT (Ki = 0.07 μM), NAT (Ki = 8--10 μM) and Nav1.5 (IC50 = 39.4 ± 2 μM)      [@B46]; [@B113]; [@B84]
                                   Norfluoxetine          9 μM             tsA 201 cells           Blocks TREK-2 (IC50 = 4.9 ± 0.5 μM), Nav1.5 (IC50 = 29.5 ± 1 μM)                                                        [@B46]; [@B84]; [@B70]
                                   Paroxetine             20 μM tested     HEK293 cells            blocks TREK-2 (at 20 μM tested), SERT (Kd = 0.13 nM), GIRK and Kv3.1                                                    [@B39]; [@B49]
                                   Citalopram             100 μM tested    HEK293 cells            blocks TREK-2 (at 100 μM tested), SERT, Kv1.5 (IC50 = 2.8 ± 1.1 μM) and L-type Ca^2+^ channels (IC50 = 60.3 ± 8.5 μM)   [@B49]
                                   Escitalopram           81.94 μM         HEK293 cells            nd                                                                                                                      [@B57]
  Antipsychotics                   Fluphenazine           4.7 μM           COS cells               Block TREK-2 (at 10 μM tested), no effect on TRAAK channels at 10 μM                                                    [@B101]
                                   Chlorpromazine         2.7 μM                                                                                                                                                           
                                   Haloperidol            5.5 μM                                                                                                                                                           
                                   Flupenthixol           2 μM                                                                                                                                                             
                                   Loxapine               19.7 μM                                                                                                                                                          
                                   Pimozide               1.8 μM                                                                                                                                                           
                                   Clozapine              10 μM tested                                                                                                                                                     
  DHP Ca^2+^ channel antagonists   Amlodipine             0.43 μM          Bovine AZF              Block L-type Ca^2+^-channels                                                                                            [@B59]
                                   Niguldipine            0.75 μM                                                                                                                                                          
  Other TREK-1 blockers            SID1900                29.72 μM         HEK293 cells            nd                                                                                                                      [@B118]
                                   l-NBP, d-NBP, ld-NBP   0.06 ± 0.03 μM   CHO cells               nd                                                                                                                      [@B44]
                                   L-methionine           1 mM             Bladder smooth muscle   nd                                                                                                                      [@B53]
                                   Lig4-4                 2.06 μM          CHO cells               Blocks Kv2.1, Kv1.5, Kv3.1, hERG and neuronal Na^+^ and Ca^2+^channels (IC50 = 30 μM)                                   [@B110]
                                                                                                                                                                                                                           

Selective Serotonin Reuptake Inhibitors (SSRI) is a family of small molecules with a high affinity for the serotonin transporter, SERT ([@B39]). SERT blockade generates an accumulation of serotonin in the synaptic clefts and displays antidepressant effects in clinic. In addition, at clinical concentrations, SSRI and fluoxetine antagonize TREK-1 channel (IC~50~ = 19 μM for fluoxetine and IC~50~ = 9 μM for Norfluoxetine, its active metabolite) ([@B46]). Other SSRIs such as paroxetine, citalopram or escitalopram also block TREK-1 with different potencies. However, SSRIs are not specific for TREK-1 since they target TREK-2, Nav1.5, and L-type Ca^2+^ channels ([@B113]; [@B84]; [@B70]).

Antipsychotic drugs used to treat psychosis, like schizophrenia and bipolar disorder, were shown to be potent blockers of TREK-1 channels. They antagonize TREK-1 and TREK-2 but do not affect TRAAK channels ([Table 1](#T1){ref-type="table"}; [@B101]). TREK-1 blockade was observed with both typical and atypical antipsychotic. For example, chlorpromazine and Loxapine block dose-dependently TREK-1 channels with IC~50~ of 2.7 and 19.7 μM ([@B101]). These data demonstrate a potential link between TREK-1, schizophrenia and bipolar disorder.

Dihydropyridine analogs such as amlodipine or niguldipine are L-type Ca^2+^ channel blockers. It has been shown that they also block TREK-1 with high affinity (IC~50~ = 0.43 and 0.75 μM for amlodipine and niguldipine, respectively). In addition, mice lacking the L-type channel Cav1.3 display an antidepressant-like phenotype ([@B12]). The compound SID1900 blocks TREK-1 with an IC~50~∼30 μM and was shown to produce antidepressant-like properties in a rat model of chronic unpredictable mild stress (CUMS) ([@B118]). SID1900 effect was comparable to spadin. Still there is no evidence about other possible targets of SID1900 and more data are needed to conclude about its specificity. Finally, other molecules were reported to block TREK-1 channels and provide neuroprotection against ischemia and stroke such as 3-n-butylphtalide (NBP) and its analog lig4-4 ([@B44]; [@B110]). However, if information is lacking about the specificity of NBP, lig4-4 was reported to affect hERG channel, voltage-gated K^+^ channels (K~v~), neuronal Na^+^ and Ca^2+^ channels, which could limit its development as potential neuroprotective molecule.

### TREK-1 Activators

TREK-1 channel is activated by volatile general anesthetics such as chloroform, diethyl ether, halothane and isoflurane and it was shown that the C-terminal part is critical for its activation ([Table 2](#T2){ref-type="table"}; [@B78]). If the chloroform seems to be selective for TREK-1 channels with an EC~50~ (0.2--1.6 mM), halothane and isoflurane activate both TREK-1 and TASK channels. Furthermore, diethyl ether opens TREK-1 but decrease TASK channel activity ([@B78]). In contrast to general anesthetics, local anesthetics like bupivacaine behave as inhibitors of TREK-1 ([@B50]). AA and other PUFAs open TREK-1 channels in dose-dependent manner ([@B79]). Channel opening by AA, α-linolenic acid (ALA), and docosahexaenoic acid (DHA) is thought to contribute to neuroprotection ([@B52]). If SSRI antidepressants and antipsychotics drugs act as TREK-1 blockers, mood stabilizers such as lithium chloride and antiepileptics drugs like gabapentine, valproate and carbamazepine were reported to activate TREK-1 channel ([@B49]). The tetrazole based compound BL-1249 showed an interesting TREK-1 activation with an EC~50~ of around 1.5 μM *in vitro* in cultured human urinary bladder myocytes ([@B100]). In a pancreatic carcinoma cell line, BL-1249 activates dose-dependently TREK-1 with an IC~50~ = 2 ± 2 μM ([@B92]). Recent studies provided more insights into the action mechanism of BL-1249. Indeed, it was shown that BL-1249 activates the selectivity filter C-type gate and activates selectively TREK-1 and TREK-2 channels 10-fold stronger than TRAAK channels ([@B83]). In addition, BL-1249 action requires the C-terminal tail of the channel for the activation and the transmembrane domains M2 and M3 are critical for its selectivity ([@B83]). Following the screening of more than 106,000 small molecules, an activator of TREK-1 named ML67 and its optimized analog ML67-33 were identified ([@B3]). Then after, two molecules with higher potency were recently developed by the same laboratory, ML335 and ML402 which potentiate TREK-1 activity with EC~50~ of 5.2 ± 0.8 μM and 5.9 ± 1.6 μM, respectively ([Table 2](#T2){ref-type="table"}; [@B61]). ML335 and ML402 bind and activate a cryptic binding pocket within the C-type gate selectivity filter of TREK-1 channel ([@B61]). Non-steroid anti-inflammatory drugs (NSAIDs) such as flufenamic acid, niflumic acid and mefenamic acid were reported to activate TREK-1 channels independently of cyclooxygenase COX inhibition ([@B104]). Caffeic acid derivatives were reported to activates TREK-1 channel and provide potent analgesic effect *in vivo* ([@B87]; [@B108]). Finally, small molecule GI-530159 was described as TREK-1 opener which reduces small DRG neurons excitability ([@B63]). However, GI-530159 is not selective for TREK-1 channels since it activates also TREK-2 with no significant effect on TRAAK channels ([@B63]).

###### 

TREK-1 activators.

                                       Molecule           EC50                                   Cell type                                 Specificity                                                                                                                                                                                                                                                                                                                                             References
  ------------------------------------ ------------------ -------------------------------------- ----------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------
  Neuroprotective agents               Riluzole           Transient activation (100 μM tested)   COS cells                                 Activates TRAAK (EC50∼60 μM), blocks TTX-sensitive (IC50 = 90 μM) and TTX-resistant (IC50 = 143 μM) sodium channels. It antagonizes Ca^2+^ entry induced by glutamic acid (IC50 = 0.30 ± 0.07 μM) or by NMDA (IC50 = 12.8 ± 2.4 μM). Riluzole inhibits glutamate release in the caudate nucleus (10 μM tested) and the hippocampus (10--30 μM tested)   [@B15]; [@B67]; [@B42]; [@B95]; [@B25]
  Mood stabilizers                     Lithium            Maximum of activation at 1 mM          HEK293 cells                              nd                                                                                                                                                                                                                                                                                                                                                      [@B49]
                                       Gabapentin         100μM tested                                                                     nd                                                                                                                                                                                                                                                                                                                                                      [@B49]
                                       Valproate          100 μM tested                                                                    nd                                                                                                                                                                                                                                                                                                                                                      [@B49]
                                       Carbamazepine      Maximum of activation at 100 μM                                                  nd                                                                                                                                                                                                                                                                                                                                                      [@B49]
  Carbazole-based                      ML67               EC50 = 213 ± 1.2 μM                    Xenopus oocytes                           Activates TREK-2 (EC50∼250 μM) and TRAAK                                                                                                                                                                                                                                                                                                                [@B3]
                                       ML67-33            EC50 = 36.3 ± 1 μM                     Xenopus oocytes                           Activates TREK-2 (EC50 = 30.2 ± 1.4 μM) and TRAAK (EC50 = 27.3 ± 1.2 μM)                                                                                                                                                                                                                                                                                
                                                          EC50 = 9.7 ± 1.2 μM                    HEK293                                                                                                                                                                                                                                                                                                                                                                                            
                                       ML335              EC50 = 14.3 ± 2.7 μM                   Xenopus oocytes                           Activates TREK-2 (EC50 = 5.2 ± 0.5 μM), no effect on TRAAK                                                                                                                                                                                                                                                                                              [@B61]
                                                          EC50 = 5.2 ± 0.8 μM                    HEK293                                                                                                                                                                                                                                                                                                                                                                                            
                                       ML402              EC50 = 13.7 ± 7 μM                     Xenopus oocytes                           Activates TREK-2 (EC50 = 5.9 ± 1.6 μM), no effect on TRAAK                                                                                                                                                                                                                                                                                              
                                                          EC50 = 5.9 ± 1.6 μM                    HEK293                                                                                                                                                                                                                                                                                                                                                                                            
  Polyunsaturated fatty acids (PUFA)   Arachidonic acid   (0.1--10 μM) tested                    COS cells                                 Activates TREK-2 (1--10 μM), no effect on TRAAK (0.01--100 μM)                                                                                                                                                                                                                                                                                          [@B79]
  General volatile anesthetics         Chloroform         (0.2--1.6 mM)                          COS cells                                 Selective for TREK-1                                                                                                                                                                                                                                                                                                                                    [@B78]
                                       Halothane          (0.04--4 mM)                                                                     Activates TASK channels                                                                                                                                                                                                                                                                                                                                 
                                       Isoflurane         2 mM tested                                                                      Activates TASK channels                                                                                                                                                                                                                                                                                                                                 
                                       Diethyl ether      0.8 mM tested                                                                    Decrease TASK channel activity                                                                                                                                                                                                                                                                                                                          
  Analgesics (NSAIDs)                  Fenamate           EC50∼100 μM                            COS cells                                 Activates TREK-2 (EC50∼100 μM) and TRAAK (\>100 μM)                                                                                                                                                                                                                                                                                                     [@B97]
                                       Flufenamic acid    250 ± 35% at 100 μM                    TsA201 cells                              nd                                                                                                                                                                                                                                                                                                                                                      [@B104]
  Tetrazole-based                      BL-1249            EC50 = 1.49 ± 0.08 μM                  Cultured human urinary bladder myocytes   nd                                                                                                                                                                                                                                                                                                                                                      [@B100]
                                                          EC50 = 2 ± 2 μM                        Pancreatic ductal adenocarcinoma          nd                                                                                                                                                                                                                                                                                                                                                      [@B92]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

### TREK-1 Modulators

Riluzole ([Table 2](#T2){ref-type="table"}) is a neuroprotective molecule marketed as an anticonvulsant drug. Its action mechanism involves the blockade of glutamate receptors. It is also prescribed to prolong the survival of patient suffering from amyotrophic lateral sclerosis. Besides, riluzole was shown to act as a transient TREK-1 activator within 30 s and strong inhibitor after 90 s ([@B25]). The dual activity on TREK-1 is thought to be mediated through cyclic Adenosine MonoPhosphate (cAMP) activation of PKA. On the other hand, riluzole produces a sustained activation of TRAAK without an inhibition.

TREK-1 and CNS Disorders
------------------------

TREK-1 channels show a widespread distribution in rat and mouse brains ([@B36]; [@B98]). It is rational to imagine multiple roles that TREK-1 can play in the CNS. In this part of the review, we will explain in depth why TREK-1 channel became a very promising target in numbers of pathologies that affect the CNS ([Figure 3](#F3){ref-type="fig"}).

### TREK-1 in Depression

The role of TREK-1 in depression was demonstrated in mice invalidated for *kcnk2*, the gene encoding for TREK-1 ([@B38]). TREK-1 knock-out mice displayed a phenotype resistant to depression in five different mouse models of depression: the Porsolt forced swim test (FST), the tail suspension test (TST), the conditioned suppression of motility test (CSMT), the learned helplessness test (LH), and the novelty-suppressed feeding test (NSF) ([Table 3](#T3){ref-type="table"}; [@B38]). The behavior of *kcnk2^-/-^* mice was similar to those treated acutely or chronically with classical antidepressants like fluoxetine ([@B38]). *Kcnk2*-deficient mice show an increase in serotonin (5-HT) neurotransmission in the DRN neurons. Deletion of TREK-1 increases neurogenesis induced with a chronic treatment with antidepressants ([@B38]). Blocking TREK-1 has become a novel strategy to design new generation of antidepressants. At the concentrations used clinically, SSRIs inhibits TREK-1 channels ([@B46]).

###### 

TREK-1 in CNS pathologies.

  Pathology                TREK-1 expression                                                        Potential treatment                                                                                                                            References                                                                                                                             
  ------------------------ ------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------ ---------------
  Depression               nd                                                                       nd                                                                                                                                             ↑ in the frontal cortex 3 weeks after CMS in rat No change in the hippocampus   TREK-1 blockers as potential treatment in depression   [@B14]
                                                                                                                                                                                                                                                   Fluoxetine per os daily for 3 weeks                                                                                                    
                                                                                                                                                                                                                                                   Reverse TREK-1 overexpression in the frontal cortex                                                                                    
  Ischemia                 Broad distribution in the cortex and CA1 (glia and neurons)              ↑ in the hippocampus at 3 and 30 days after BCAL *In situ* hybridization: ↑ in the cortex and hippocampus 7 and 30 days after BCAL ([@B117])   in the hippocampus 7 and 30 days after MCAO                                     TREK-1 openers as potential treatment in ischemia      [@B109]
                           ↑ in the cortex and the hippocampus after 3, 7, and 30 days after MCAO                                                                                                                                                                                                                                                                                         
  Pain perception          TREK-1 expression in DRG sensory neurons                                 ↑ in DRG of CCI mice                                                                                                                           ↑ in DRG of CCI mice                                                            TREK-1 openers as potential analgesics                 [@B1]; [@B34]
  Post-stroke depression   Broad distribution in PFC, CA1, CA3, and DG                              **No treatment, after 31 days of MMCAO**                                                                                                                                                                                       [@B57]                                                 
                                                                                                    ↑ in PFC, CA3 and DG                                                                                                                           ↑ in PFC, CA1, CA3 and DG                                                       TREK-1 blockers as potential treatment in PSD          
                                                                                                    **Escitalopram (3 weeks)**                                                                                                                                                                                                                                                            
                                                                                                    ↓ in PFC, CA3 and DG                                                                                                                           ↓ in PFC, CA1,CA3 and DG                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                          

Spadin was previously described as a specific blocker of TREK-1 with a high affinity (IC~50~ = 40--70 nM) ([@B68]; [@B23], [@B22]). Spadin consists in 17-amino acid peptide synthesized from the propeptide (PE). PE is 44 amino acids generated from the maturation of sortilin by the cleavage of the prosortilin with furin ([@B74]). Spadin binds with high affinities both TREK-1 and sortilin/neurotensin receptor 3 (NTSR3). Spadin by blocking TREK-1 generates mice with depression-resistance phenotype in several depression tests after only 4 days of treatment. Similarly to *kcnk2*^-/-^ mice, spadin enhances 5-HT neurotransmission in DRN serotonergic neurons ([@B68]). In *in vitro* experiments, spadin stimulates MAPK and PI3K pathways in time and concentration-dependent manner. Spadin at 100 nM increases the phosphorylation of ERK1/2 and Akt but does not affect the phosphorylation of mTOR, suggesting an original mechanism of action of spadin different from the other fast-acting antidepressant ketamine which was demonstrated to be mTOR-dependent ([@B20]). Spadin has protective effects on neurons against staurosporine-induced Caspase-3 apoptosis through the specific activation of the PI3K pathway. Spadin increases transiently and after 8 h the mRNA expression of PSD-95 and synapsin, two markers of synaptogenesis in the brain. This increase is associated with a transient BDNF increase only after 5 h. Spadin increases also the proportion of mature spines in cortical neuronal culture. *In vivo*, daily spadin administration for 4 days increased mRNA expression of BDNF, PSD-95 and synapsin after only 7 days in the hippocampus. However, in the prefrontal cortex (PFC), only BDNF was enhanced after 3 weeks ([@B20]).

The FST antidepressant activities of spadin disappear after 7 h after an acute treatment. To improve the bioavailability and the *in vivo* stability of spadin, retro-inverso analogs of spadin were designed and screened on the cell line stably expressing the human TREK-1 ([@B105]). Two analogs, 3 and 8, were identified. They prolong the antidepressant activity from 7 to 16 h in FST. However, due to some issues concerning *in vitro* toxicity of analog 3 and 8 at higher concentrations, other strategies were conducted in order to ameliorate the benefit/risk ratio. By shortening spadin sequence, a peptide PE 22-28 containing only 7 amino acids was identified as the shortest efficient molecule displaying an antidepressant activity ([@B23], [@B22]). The role of TREK-1 in mice was supported by other studies in human like STAR(^∗^)D which highlights a strong association between resistance to SSRIs and the existence of four single nucleotide polymorphisms (SNP) in *kcnk2* gene ([@B80]). Another SNP, rs6686529 located in *kcnk2* gene was found to be associated with major depression disorder and response to antidepressant treatment ([@B58]). All these data highlight the key role of TREK-1 in depression and the need to design blockers of TREK-1 as promising original antidepressant ([Figure 3](#F3){ref-type="fig"}).

### TREK-1 in Neuroprotection

#### TREK-1 in epileptogenesis

TREK-1 is expressed in GABA-containing interneurons in the cortex and the hippocampus ([@B36]). *In vivo*, It was reported that TREK-1 activators PUFA such as α-linolenic acid protect rats treated with the glutamate receptor agonist, kainic acid (KA) against seizures and hippocampal lesions ([@B52]). Moreover, PUFA neuroprotection was observed in another model of seizures using glutamatergic neurons. This effect was associated with the inhibition of the glutamatergic neurotransmission ([@B52]). TREK-1 deficient mice were shown to be more vulnerable to develop epileptic seizures triggered by KA and pentylenetetrazol (PTZ, GABA~A~ receptor antagonist) ([@B37]). The expression of *c-fos*, a marker of neuronal excitability was increased in CA3 pyramidal neurons following treatment with KA ([@B37]). Linolenic acid and lysophosphatidylcholine (LPC) decrease KA-induced seizures in wild-type mice. However, no effect was observed in mice lacking TREK-1 channels ([@B37]). The protective effects of linolenic acid and LPC require the presence of TREK-1 channels. Status epilepticus (SE) is a persistent repeated seizure activity for more than 5 min. Development of TREK-1 mutant (TREK-M) produced a constitutively open TREK-1 channels that showed resistance to PKA and PKC downregulation. TREK-M was able to hyperpolarize the plasma membrane and decrease spontaneous firing of hippocampal neurons in culture ([@B21]). *In vivo* administration of a recombinant adenoassociated virus (AAV)-mediated delivery of TREK-M in both entorhinal cortex and hippocampal CA3 regions, reduced by 50% the duration of SE in a mouse model of SE induced with lithium and pilocarpine. AAV-TREK-M prevented neuronal death in both entorhinal cortex and CA3 after injection ([Table 3](#T3){ref-type="table"}; [@B21]). Since TREK-1 opening results in neuroprotection against epileptic episodes, blocking this AA-activated K~2P~ channel could in contrast be deleterious. Surprisingly, TREK-1 antagonist spadin does not enhance seizures induced by KA or PTZ when injected to mice. More interestingly, mice treated with spadin show more resistance to develop generalized convulsions and to induce death ([@B73]; [@B22]).

#### TREK-1 in ischemia

Using a model of global ischemia, results from transient bilateral occlusion of common carotid arteries in wild-type and knock-out TREK-1 mice showed that 74% of TREK^-/-^ mice died 3 days after ischemia whereas only 34% died in wild-type group ([@B37]). Here again, linolenic acid or LPC pretreatment were unable to protect against ischemia in TREK-1 deficient mice in contrast to wild-type mice in which mice survival was significantly increased ([@B37]). Spinal cord ischemia is induced in mice by occluding both the aortic arch and left sub-clavian artery. It was reported that 75% of *kcnk2*^-/-^ mice died 3 h after 10 min ischemia compared to only 14% of wild-type mice 24 h after ischemia ([@B37]). Furthermore, surviving TREK-1^-/-^ mice developed severe hind limb paralysis. However, no neurological deficit was observed with wild-type mice ([@B37]). In addition to neurons, astrocytes were shown to play an important role in brain ischemia. TREK-1 contributes in maintaining the highly negative membrane potential in astrocytes which is crucial in controlling cell excitability ([@B119]). In cultured cortical astrocytes and in hippocampal slices, TREK-1 is widely expressed. Cortical and hippocampal TREK-1 channels were upregulated during astrogliosis following focal ischemia ([@B109]). In hypoxic conditions, TREK-1 protein expression in astrocytes was also upregulated which increases glutamate clearance, suppressed the astrocytic marker S100β and block neuronal death ([Table 3](#T3){ref-type="table"}; [@B115]). Glutamate is the main excitatory neurotransmitter in the brain. Astrocytes release glutamate following GPCR activation. DH Woo et al. demonstrate that TREK-1 channel is involved in the fast glutamate release which requires the interaction between the N-terminal domain of TREK-1 and the G~βγ~ of the G~αi~PCR ([@B114]).

#### TREK-1 in general anesthesia

In general anesthesia, at clinical doses used for isoflurane, diethyl ether, halothane and chloroform, TREK-1 channels are activated ([@B78]). TREK-1 channel activation implies the C-terminal moiety and leads to cell hyperpolarization, decreased action potential firing and neuroprotection. The laughing gas nitrous oxide and xenon mostly exert their anesthetic effects via antagonizing NMDA receptors since they provide analgesia, euphoria and neuroprotection. They do not potentiate GABA~A~ receptors ([@B33]). Nitrous oxide and xenon were shown to open TREK-1 channels with Glu306 as a critical amino acid for the anesthetic activation of TREK-1 ([@B33]). Chloral hydrate is used in pediatrics in certain forms of epilepsy such as progressive myoclonus and refractory childhood epilepsies. Upon administration, Chloral hydrate is rapidly metabolized into its active metabolite 2,2,2-trichlorethanol (TCE) which is thought to be responsible for the chloral hydrate activity ([@B35]). TCE induces depression of the CNS by potentiating GABA~A~ receptors and inhibiting NMDA, AMPA, and Kainate receptors. It was reported that TCE also activates TREK-1 and TRAAK channels and contributes to the central anesthetic effect ([@B35]). *In vivo*, mice lacking TREK-1 channels displayed a lower sensitivity to the most potent TREK-1 activators, chloroform and halothane and also to sevoflurane, desflurane and isoflurane ([@B37]). The threshold to provoke anesthesia and the doses required for the anesthetic action were higher. Phenobarbital, a general anesthetic that does not modulate TREK-1 channels, fails to reproduce these effects in *kcnk2*^-/-^ mice. Thus, the observed effects were due specifically to TREK channel absence. Recently, *in vitro* and *in vivo* preconditioning with sevoflurane was shown to provide neuroprotection through activation of TREK-1 channels ([@B102]). Rats treated with the anesthetic sevoflurane after MCAO display neuroprotection which seems to be mediated by TREK-1 channels ([Table 3](#T3){ref-type="table"}; [@B77]).

### Role of TREK-1 in Post-stroke Depression

Given the neuroprotective role of TREK-1 channels in stroke and its involvement in the depression process. It makes sense to address the role of this K~2P~ channel in the physiopathology of post-stroke depression (PSD). Recently, several laboratories have started to investigate the potential role of TREK-1 channels in this pathology. PSD is a high prevalence neuropsychiatric disorder that takes place after stroke onset. It has been shown that TREK-1 channel expression levels were elevated in the hippocampus and the PFC in rat model of PSD ([Table 3](#T3){ref-type="table"}; [@B57]). Noteworthy, TREK-1 channel up-regulation was suppressed following chronic treatment with the TREK-1 blocker and the SSRI, escitalopram. In this PSD rat model, the main actors causing PSD in human patients were reproduced. For example, the middle cerebral artery occlusion (MCAO) surgery was set up to mimic stroke and chronic mild stress (CMS) and isolation rearing to mimic stress and psychosocial conditions, respectively ([@B57]).

### TREK-1 in Pain Perception

TREK-1 channels are known to be modulated by heat. Those K~2P~ channels are gradually and reversibly opened by temperature. Noteworthy, TREK-1 channel opening is reversed by cAMP and prostaglandin E2, two sensitizers of peripheral and central thermoreceptors. TREK-1 blockade is due to the phosphorylation of Ser333 on its C-terminal end. The thermosensitive TREK-1 channel is highly expressed and localized in small dorsal root ganglion (DRG) neurons and in central hypothalamic neurons, areas that are highly involved in pain ([@B65]). Sixty percent of sensory neurons express TREK-1 and most of them are associated with substance P. More than 40% of DRG neurons that express TREK-1 channels also express the thermal nociceptor TRPV1 channels. *In vivo*, compared to wild type mice, mice lacking *kcnk2* gene are highly sensitive to low-threshold thermal pain and mechanical stimuli ([@B1]). TREK-1 deficient mice showed an exacerbated focal inflammatory response after spinal cord injury (SCI). Furthermore, TREK-1 deficiency enhanced astrogliosis, neuronal apoptosis, demyelination and retarded motor recovery ([@B27]). Nevertheless, in other reported studies, in the DRG, the microRNA miR-183 expression was decreased and TREK-1 expression was increased in neuropathic pain induced by chronic constriction of sciatic nerve (CCI) ([Table 3](#T3){ref-type="table"}; [@B34]; [@B94]). Intrathecal injection of miR-183 alleviated pain in rat model of CCI and downregulated TREK-1 expression ([@B94]). Recently, it was reported that TREK-1 modulator riluzole prevents both sensory and motor deficits in neuropathic pain induced by the chemotherapy drug oxaliplatin ([@B85]). Nevertheless, conclusions drawn by this paper are not totally convincing because authors only consider riluzole as an activator and do not take into account its inhibitory effects. Finally, TREK-2 and TRAAK channels, the other members of TREK subfamily are characterized in the small sized DRG neurons of rats ([@B106]).

Peripheral Roles of TREK-1 Channels
-----------------------------------

### TREK-1 in the Heart

In the heart, the stretch-activated K^+^ channels (SAK) repolarize cell membrane and counterbalance the activity of stretch-activated Cation channels (SAC) which in contrast increase cation influx and cell depolarization. TREK-1 channel presents a serious candidate to form SAK in heart with the large conductance Ca^2+^-activated K^+^ channel (BK~Ca~) and K~ATP~ channels ([@B18]). In rat heart, all K~2P~ channel genes were detected in at least one heart chamber with a prevalence of TWIK-2, TASK-1 and TREK-1 expression. TREK-1 channel was highly expressed in the right ventricle ([@B60]). In rat neonatal atrial myocytes, using single channel inside-out patch, TREK-1-like current was activated by AA and internal acidosis ([@B47]). This TREK-1-like current was shown to be reversibly activated by volatile anesthetics such as chloroform, halothane and isoflurane. It was also downregulated by cAMP analogs and β-adrenergic receptor agonists ([@B99]). SAK current shared identical biophysical properties with the recombinant TREK-1 current such as the single channel conductance, no voltage-dependency and sensitivity to volatile anesthetics. In the ventricular cardiomyocytes, two variants of TREK-1 were found, large conductance and small conductance with (132 ± 5 pS) and (41 ± 5 pS), respectively, at positive potentials ([@B116]). The low-conductance TREK-1 variant was opened by mechanical stretch, internal acidification and AA. The biophysical properties of the two TREK-1 channels were similar to those displayed by the recombinant TREK-1 channels expressed in HEK293 cells. Using cardiac specific TREK-1 deficient mice, it was proposed that TREK-1 plays an essential role in sinoatrial node cell excitability ([@B103]). Recently, a heterozygous point mutation in the selectivity filter of TREK-1 channel was identified in patients diagnosed with right ventricular outflow tract (RVOT) tachycardia ([@B19]). More interestingly, TREK-M showed a hypersensitivity to stretch and permeability to sodium ions ([@B19]; [Figure 3](#F3){ref-type="fig"}).

### Role of TREK-1 in Other Tissues

In addition to the central roles of TREK-1 channels in the brain, it was thoroughly rational to think that modulating TREK-1 channels could play a peripheral role as this K~2P~ channel is expressed in number of tissues such as pancreas, prostate and smooth muscle cells ([@B72]). The pancreas and particularly the insulin secreting β-cells constitute one of the main targets of the peripheral tissues where TREK-1 and other K~2P~ channels play an important role in glucose homeostasis ([@B45]; [@B68]; [@B17]; [@B107]). Given the importance of TREK-1 channel as a key modulator of plasma membrane potential in addition to its regulation by various physical and chemical stimuli, its role in the glucose homeostasis has been investigated using spadin ([@B40]). Spadin inhibits TREK-1 channels in the pancreatic β-cell line β-TC3 ([@B68]). It is known that the regulation of insulin secretion by pancreatic β-cell is fine-tuned by a variety of hormones such as glucagon like-peptide-1 (GLP-1), leptin, estrogen, melatonin and growth hormone ([@B29]). It is well established that ATP-sensitive potassium channels (K~ATP~) play a critical role in maintaining glucose homeostasis ([@B71]). K~ATP~ channels serve as a metabolic sensor for the pancreatic β-cell. When glucose levels increase, K~ATP~ channels close, inducing a membrane depolarization resulting in the opening of Ca^2+^ channels as well as the secretion of numerous hormones and amplification of the effects of glucose and other secretagogues such as GLP-1 ([@B71]). TREK-1 blockade by spadin induces insulin secretion only upon glucose stimulation. However, in contrast to incretin hormones, spadin induces Ca^2+^ increase and insulin release through an original PKA-independent mechanism ([@B40]). TREK-1 channels are inhibited as well by the PKA phosphorylation of the Ser333 at the C-terminal moiety of the channel ([@B75]), which is the consequence of the activation of different G-protein-coupled receptors at the plasma membrane. By binding to their GLP-1 receptors, GLP-1 and its analogs such as exendin-4 are able to trigger cAMP synthesis and thus induce PKA activation leading to insulin secretion ([@B31]). Then, insulin release by β-cells is potentiated by TREK-1 closing following PKA phosphorylation. Spadin or its analogs could substitute to incretin hormone actions and could propose a therapeutic alternative in case of inefficacy of antidiabetic treatment using GLP-1 mimetics. Among the other K~2P~ channels, the mechano-sensitive K~2P~ channel TREK-1 is predominately expressed in the human detrusor channel ([@B2]). Recently, a study assessing the relationship between six SNP and the occurrence of overactive lower urinary tract symptoms (LUTS), revealed a strong association between TREK-1 polymorphisms (rs758937019-CT genotype and rs758937019-T allele) and overactive LUTS in human ([@B76]).

Conclusion and Perspectives
===========================

Since their cloning 20 years ago, the physiological importance of TREK-1 channels has continued to grow ([Figure 3](#F3){ref-type="fig"}). Today, TREK-1 channels have been shown to be important and their presence is essential in a number of physiopathological processes. Their involvement in these different processes demonstrate the necessity to design pharmacological modulators, activators or inhibitors, of these channels to correct any TREK-1-related dysfunctions.

Despites a number of studies and many molecule screenings, only few putative new drugs were identified. The activators belonging to the ML and BL series show interesting results. However, they display lower affinities (in the micromolar range) and they are not specific for TREK-1 channels as they open other K~2P~ channels. TREK-1 openers are needed in pathologies such as ischemia, epilepsy and pain. The challenge is to improve their affinity, specificity and ability to cross the blood-brain barrier. The new ML and BL series of TREK- activators have not yet been tested in pathologies such epilepsy and ischemia. It would be interesting to investigate any neuroprotection effects of these molecules in rodent models of epilepsy or ischemia. In the same time, their specificity should be improved to avoid any off-target effects resulting from modulating other K~2P~ channels.

As inhibitors, the most promising molecules are spadin and its analogs. These peptides are very specific in the K~2P~ family and display very high affinities, in the picomolar range for the shorter analogs ([@B23]). Depression is a complex mood disorder where different actors are involved. TREK-1 is definitely one of the most promising ion channel that plays a key role in the neurobiology of depression. TREK-1 blockers such as spadin and short analogs display a huge therapeutic value over the classical antidepressants prescribed nowadays. They are fast-acting with highly affinity and specificity for TREK-1. More interestingly, they cross the blood-brain barrier which facilitates their further optimization and development as antidepressant drugs useful in clinic.

In the future, in addition to looking for new TREK-1 modulators to treat neuropsychiatric disorders, it is relevant to study the role of TREK-1 channels in peripheral tissues and understand their involvement in physiopathology. An emerging area where TREK-1 is displaying a growing interest is the heart. TREK-1 expression has been shown to change in cardiac hypertrophy ([@B111]). Furthermore, a TREK-M was found to change channel permeability to sodium and cause ventricular tachycardia ([@B19]).

To conclude, the wide distribution of TREK-1 in human body, the diverse stimuli and regulations that it could respond to, and the pleiotropic roles it could play in physiology and physiopathology, make TREK-1 a promising target to explore in depth but at the same time very challenging to design modulators that are tissue-specific.
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